Work

Determinants of Human Immunodeficiency Virus Plasma Viremia

Year: 2023
Type: dissertation
Study design: Observational Study
Abstract: The Human Immunodeficiency Virus Type 1 (HIV-1) pandemic has resulted in 36.3 million deaths to date.In 2022, 39 million people were living with HIV (PLWH) worldwide.While there is no widely applicable cure, antiretroviral therapy (ART) prevents AIDS by halting full rounds of viral replication.Prior to ART initiation, PLWH have variable levels of plasma HIV RNA (viremia), ranging from <50 to >1 million HIV RNA copies/mL.What determines different levels of viremia in untreated individuals is not fully understood but is likely due to a combination of different levels of viral gene expression and host immune-control.I hypothesized that individuals with low levels of viremia (60-2,000 HIV-1 RNA copies/mL) have a low fraction of infected cells producing the precursors necessary to generate virus particles, while individuals with high levels of viremia (>5,000 HIV-1 RNA copies/mL) have a high fraction of infected cells with these precursors.I used HIV-1 unspliced RNA (HIV usRNA) as a surrogate for the precursors required to generate viral particles since this RNA is the form that is packaged into viral particles.However, after measuring the fraction of peripheral blood mononuclear cells (PBMC) with HIV usRNA in PLWH with high and low levels of viremia, I found that levels of plasma viremia were not associated with the fraction of infected cells that contain HIV usRNA; but rather, with the total number of infected PBMCs.These findings show that natural control of HIV replication typically occurs downstream of HIV usRNA synthesis, not prior to it, as was previously thought, changing our understanding of HIV pathogenesis and redirecting the design of strategies towards achieving ART-free viral remission.
Language: English
Subfield: Virology
Open Access status: green
OpenAlex ID: W7046516302
Cites: 102
Cited by:
Related to: 10